Findings

What do systematic reviews say?

4 questions · 4 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 75%Low 1 · 25%Moderate 0 · 0%High 0 · 0%

Ursodeoxycholic acid vs placebo or no intervention

All‐cause mortality · patients with primary biliary cirrhosis.

It is very uncertain whether ursodeoxycholic acid changes all‐cause mortality compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 0.97 [0.67, 1.42]
14 studies · 1391 participants
Very low

Ursodeoxycholic acid vs placebo or no intervention

All‐cause mortality or liver transplantation · patients with primary biliary cirrhosis.

It is very uncertain whether ursodeoxycholic acid changes all‐cause mortality or liver transplantation compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RR 0.96 [0.74, 1.25]
15 studies · 1419 participants
Very low

Ursodeoxycholic acid vs placebo or no treatment

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

Summary of findings: Ursodeoxycholic acid may leads to lower all‐cause mortality at 100 days post‐transplant ( compared with placebo or no treatment (low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 0.7 [0.5, 0.99]
4 studies · 612 participants
Low

Bezafibrate vs ursodeoxycholic acid

All‐cause mortality · patients with primary biliary cirrhosis.

It is very uncertain whether bezafibrate changes all‐cause mortality compared with ursodeoxycholic acid (very low certainty).

1 finding from 1 review

Bezafibrate for primary biliary cirrhosis 2012 · Cochrane Headline outcomes only
RD 0
2 studies · 69 participants
Very low